Anti-nausea drug kills brain tumour cells

25 Mar 2013

1

New research from the University of Adelaide has shown for the first time that the growth of brain tumours can be halted by a drug currently being used to help patients recover from the side effects of chemotherapy.

The discovery has been made during a study into the relationship between brain tumours and a peptide associated with inflammation in the brain, called "substance P".

Substance P is commonly released throughout the body by the nervous system, and contributes to tissue swelling following injury. In the brain, levels of substance P greatly increase after traumatic brain injury and stroke.

"Researchers have known for some time that levels of substance P are also greatly increased in different tumour types around the body," says Dr Elizabeth Harford-Wright, a postdoctoral fellow in the University's Adelaide Centre for Neuroscience Research.

"We wanted to know if these elevated levels of the peptide were also present in brain tumour cells, and if so, whether or not they were affecting tumour growth. Importantly, we wanted to see if we could stop tumour growth by blocking substance P."

Harford-Wright found that levels of substance P were greatly increased in brain tumour tissue.

Knowing that substance P binds to a receptor called NK1, Harford-Wright used an antagonist drug called Emend to stop substance P binding to the receptor. Emend is already used in cancer clinics to help patients with chemotherapy-induced nausea.

The results were startling.

"We were successful in blocking substance P from binding to the NK1 receptor, which resulted in a reduction in brain tumour growth - and it also caused cell death in the tumour cells," Harford-Wright says.

"So preventing the actions of substance P from carrying out its role in brain tumours actually halted the growth of brain cancer.

"This is a very exciting result, and it offers further opportunities to study possible brain tumour treatments over the coming years."

The research was funded by the NeuroSurgical Research Foundation (NRF), which is celebrating 50 years of supporting neurosurgical research in Australia and at the University of Adelaide.

Latest articles

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

Toyota set for third straight quarterly profit drop as costs and tariffs weigh

Toyota set for third straight quarterly profit drop as costs and tariffs weigh